

<b>Type</b>	<b>POSTER</b>
P01	Cardiovascular and Metabolic
P02	Addiction Disorders
P03	Pharmacogenetics
P04	Pharmacognosy, Phytotherapy and Nutraceuticals
P05	Cancer Pharmacology
P06	Pediatric Pharmacology
P07	Pain Pharmacology
P08	Gastrointestinal Pharmacology
P09	Respiratory Pharmacology
P10	Gender Pharmacology and Toxicology
P11	Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics & RWE
P12	Immunopharmacology
P13	Environmental Impact of Drugs
P14	Inflammation
P15	Neurodegenerative Diseases
P16	Rare Diseases and Orphan Drugs
P17	Neuropsychopharmacology
P18	Obesity, Metabolic Syndrome and Eating Disorders
<b>Type</b>	<b>SYMPOSIUM</b>
SY01	From viscera to soma: mechanisms and drug targets for the treatment of pain
SY02	CGRP: migraine and beyond
SY03	Intestinal Microbiota in Extra-Digestive Disorders
SY04	Drug targeting of cancer cells

SY05	Targeting of tumor microenvironment cells and structures
SY06	New Therapeutic Approaches in Endothelial and Cardiac Dysfunction
SY07	Substance Use Disorder in adolescence and adulthood: neurobiological adaptations, behavioral outcomes, and their clinical relevance
SY08	Synaptic and Cellular Communication in Neurodegeneration: Mechanisms and Therapeutic Opportunities
SY09	Real world evidence of biologic drugs in immune mediated inflammatory diseases
SY10	Post-marketing surveillance and appropriate drug utilization
SY11	Therapeutic drug monitoring as a measure of appropriateness in adult and pediatric populations
SY12	Tissue Damage and the Immune Microenvironment: Emerging Immunoregulatory Mechanisms and therapeutic perspectives
SY13	Joint SIF–SIICA Symposium: Targeting Immunometabolism – Young Investigators Rewiring Immune Function for Next-Generation Therapies
SY14	Natural compounds and barrier functions: new evidence between gastroprotection, metabolism, and aging
SY15	Phytotherapeutics and the Central nervous system
SY16	Stress across the lifespan: mechanistic insights and novel therapeutic perspectives
SY17	Deconstructing Neurodevelopmental Disorders: From Neurobiological Mechanisms to Clinical Trials
SY18	Advanced Pulmonary disorders: emerging targets and technologies
SY19	The metastatic partnership: vascular, stromal and immune interaction in the journey of circulating tumor cells
SY20	Convergent Modulation of Neuroinflammation and Immunity Through Shared Molecular Pathways in CNS Pathologies

SY21	De novo drug design, polypharmacy, repurposing, and AI-Driven discovery in rare diseases
SY22	Novel and 3R-compliant platforms for early translational research in rare diseases
SY23	At the crossroad of eating disorders and addictive behaviors: converging mechanisms towards translational treatment opportunities
SY24	Pharmacological innovations for the management of metabolic disorders and their comorbidities
SY25	Role of sex differences in the modulation of lipid-derived mediators across different pathological conditions
SY26	Precision medicine: oncology and beyond
SY27	Environmental stress as a driver of neuro-immuno-metabolic disease: risk factors and vulnerability mechanisms
SY28	Advances in Alternative Research Methods: from drug discovery to personalized medicine
SY29	Biotechnological drugs in modern pharmacology: emerging classes and therapeutic innovations
SY30	Frailty in Complex Comorbidities: From Mechanisms to Emerging Therapeutic Strategies